Debt-to-equity of Estrella Immunopharma, Inc. from 30 Jun 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Estrella Immunopharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2022 to 30 Sep 2025.
  • Estrella Immunopharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -169%, a 1126% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Estrella Immunopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -169% -185% -1126% 30 Sep 2025
Q2 2025 -275% -331% -587% 30 Jun 2025
Q1 2025 313% +139% +80% 31 Mar 2025
Q4 2024 46% +1784% 31 Dec 2024
Q3 2024 16% +205% 30 Sep 2024
Q2 2024 56% +113% 30 Jun 2024
Q1 2024 174% +220% 31 Mar 2024
Q4 2023 -1738% -1672% -2538% 31 Dec 2023
Q3 2023 -188% -86% -83% 30 Sep 2023
Q2 2023 -56% +105% +65% 30 Jun 2023
Q1 2023 -46% 31 Mar 2023
Q4 2022 -66% 31 Dec 2022
Q3 2022 -103% 30 Sep 2022
Q2 2022 -161% 30 Jun 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.